<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295863</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-1718</org_study_id>
    <nct_id>NCT04295863</nct_id>
  </id_info>
  <brief_title>Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers</brief_title>
  <official_title>A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized research study of drugs nivolumab and pembrolizumab in patients with locally&#xD;
      advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs&#xD;
      can be given less often then the currently approved schedule. This trial will compare drug&#xD;
      levels from the blood from standard interval dosing levels versus taking the drugs less&#xD;
      often.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2020</start_date>
  <completion_date type="Anticipated">April 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 12, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Noninferiority margin of extended interval dosing compared to standard dosing</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the noninferiority of pharmacokinetic success, defined as drug trough levels above the target concentration of 1.5 Âµg/mL. Evaluable patients will be categorized as success or failure for this primary objective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the efficacy of extended interval and standard interval dosing</measure>
    <time_frame>2 years</time_frame>
    <description>To compare the correlation of extended interval and standard interval dosing, as based on a combination of time-to-treatment discontinuation (TTD) and overall survival (OS). This secondary analysis will include all patients who received at least one dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>standard interval dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>extended interval dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab Standard</intervention_name>
    <description>For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks</description>
    <arm_group_label>standard interval dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Standard</intervention_name>
    <description>For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks</description>
    <arm_group_label>standard interval dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab Extended</intervention_name>
    <description>For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks</description>
    <arm_group_label>extended interval dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Extended</intervention_name>
    <description>For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks</description>
    <arm_group_label>extended interval dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with locally advandced or metastatic cancer whose physician has determined&#xD;
             they are candidates for treatment with nivolumab or pembrolizumab&#xD;
&#xD;
          -  18 years old or older&#xD;
&#xD;
          -  Measurable disease per RECIST criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously received immune checkpoint inhibitors or investigational&#xD;
             monoclonal antibody therapy.&#xD;
&#xD;
          -  Patients whose treatment plan is to receive ipilimumab or other anti-CTLA4 monoclonal&#xD;
             antibody in combination with either nivolumab or pembrolizumab.&#xD;
&#xD;
               -  Ipilimumab and nivolumab combination are not eligible for this trial.&#xD;
&#xD;
               -  (Note: Patients whose planned treatment is the combination of anti-PD-1 and&#xD;
                  tyrosine kinase inhibitor such as pembrolizumab-axitinib or the combination of&#xD;
                  traditional cytotoxic chemotherapy and anti-PD-1 are eligible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ratain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Personalized Cancer Care Consortium</last_name>
    <phone>773.702.1220</phone>
    <email>PhaseIICRA@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Of Chicago Medicine Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Intake</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Ratain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SSM Health Cancer Care</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Roberts</last_name>
      <phone>608-410-2769</phone>
      <email>terri.roberts@ssmhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Schultz</last_name>
      <phone>608-410-2774</phone>
      <email>nicole.schultz1@ssmhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amit Sanyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

